Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionCompagnie Lombard Odier SCmA
Latest Disclosed Ownership13,081 shares
Latest Disclosed Value $ 5,841,190
Compagnie Lombard Odier SCmA ownership in VRTX / Vertex Pharmaceuticals Incorporated

On April 15, 2026 - Compagnie Lombard Odier SCmA filed a 13F-HR form disclosing ownership of 13,081 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $5,841,190 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 16, 2026 disclosing 12,665 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 3.28% during the quarter. The current value of the position is $5,844,983 USD.

Compagnie Lombard Odier SCmA has a history of taking positions in derivatives of the underlying security (VRTX) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

VRTX / Vertex Pharmaceuticals Incorporated Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-04-15 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 13,081 416 3.28 5,841 1.74 0.0384
2026-01-16 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 12,665 100 0.80 5,742 16.69 0.0624
2025-11-06 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 12,565 0 0.00 4,921 -12.03 0.0543
2025-07-15 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 12,565 0 0.00 5,594 -8.18 0.0737
2025-04-16 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 12,565 3,000 31.36 6,092 58.17 0.0747
2025-01-30 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 9,565 -864 -8.28 3,852 -20.60 0.0568
2024-10-11 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 10,429 3,200 44.27 4,850 43.15 0.0754
2024-07-18 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 7,229 2,929 68.12 3,388 88.54 0.0573
2024-05-01 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,300 3,000 230.77 1,797 240.34 0.0318
2024-01-16 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,300 0 0.00 529 16.81 0.0098
2023-10-23 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,300 -600 -31.58 452 -32.34 0.0105
2023-08-07 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,900 0 0.00 669 11.71 0.0187
2023-05-01 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,900 -3,614 -65.54 599 -62.44 0.0150
2023-02-14 2022-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 5,514 4,214 324.15 1,592 323.40 0.0426
2023-02-13 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,514 4,214 2 0.0000
2022-11-09 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,300 -330 -20.25 376 -18.26 0.0108
2022-08-11 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,630 0 0.00 460 8.24 0.0117
2022-04-27 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,630 0 0.00 425 18.72 0.0090
2022-02-09 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,630 1,250 328.95 358 418.84 0.0071
2021-10-28 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 380 0 0.00 69 -9.21 0.0015
2021-07-15 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 380 130 52.00 76 40.74 0.0017
2021-04-23 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 250 250 54 0.0012
2020-11-12 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -325 -100.00 0 -100.00
2020-08-14 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 325 75 30.00 94 59.32 0.0032
2020-05-13 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 250 250 59 0.0025
2019-05-13 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -300 -100.00 0 -100.00
2019-02-13 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 300 -200 -40.00 50 -47.92 0.0020
2018-11-13 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 500 0 0.00 96 12.94 0.0034
2018-08-10 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 500 500 85 0.0031
2015-08-14 2015-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -537 -100.00 0 -100.00
2015-05-13 2015-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 537 537 63 0.0024
2015-02-13 2014-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -1,818 -100.00 0 -100.00
2014-11-14 2014-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,818 -4,371 -70.63 204 -65.19 0.0082
2014-08-14 2014-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,189 2,506 68.04 586 124.52 0.0233
2014-08-14 2014-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,683 1,357 58.34 261 50.87 0.0108
2014-08-14 2013-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,326 2,326 173 0.0073
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2023-08-07 2023-06-30 13F VERTEX PHARMACEUTICALS CALL Call 0 0 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.